Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Thériault, Brigitte L ^a   Basavarajappa, Halesha D ^b   Lim, Harvey ^a,c   Pajovic, Sanja ^a   Gallie, Brenda L ^a,c,d,e   Corson, Timothy W ^b,f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; KINESIN; MICRORNA; MICRORNA 144; MICRORNA 382; MICRORNA 93; PROTEIN KIF 14; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG; KIF14 PROTEIN, HUMAN; ONCOPROTEIN; SMALL INTERFERING RNA; SP1 PROTEIN, HUMAN; YY1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PROMOTER REGION; REGULATORY SEQUENCE; TRANSCRIPTION REGULATION; CHROMATIN IMMUNOPRECIPITATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HELA CELL LINE; METABOLISM; METASTASIS; MITOSIS; OVARY TUMOR; PROGNOSIS; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; KINESIN; MITOSIS; NEOPLASM METASTASIS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; UP-REGULATION; YY1 TRANSCRIPTION FACTOR;

EID: 84898740060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091540     Document Type: Article

References (54)

1. Corson TW, Huang A, Tsao MS, Gallie BL (2005) KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 24: 4741-4753. (Pubitemid 41076292)
2. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, et al. (2007) Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 46: 118-129. (Pubitemid 44913377)
3. Theriault BL, Corson T.W. (2012) Kinesin Family Member 14 (KIF14). Atlas of Genetics and Cytogenetics in Oncology and Haematology.
4. Corson TW, Gallie BL (2006) KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 119: 1088-1094. (Pubitemid 44116918)
5. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, et al. (2007) KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 13: 3229-3234. (Pubitemid 46944906)
6. Markowski J, Oczko-Wojciechowska M, Gierek T, Jarzab M, Paluch J, et al. (2009) Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays. J Physiol Pharmacol 60 Suppl 1: 57-63.
7. Markowski J, Tyszkiewicz T, Jarzab M, Oczko-Wojciechowska M, Gierek T, et al. (2009) Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol 266: 1501-1507.
8. Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL (2012) Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer 130: 1844-1854.
9. Wang Q, Wang L, Li D, Deng J, Zhao Z, et al. (2013) Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol 37: 79-84.
10. Yang T, Zhang XB, Zheng ZM (2013) Suppression of KIF14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome. Cancer Sci 104: 552-557.
11. Filges I, Nosova E, Bruder E, Tercanli S, Townsend K, et al. (2013) Exome sequencing identifies mutations in KIF14 as a novel cause of an autosomal recessive lethal fetal ciliopathy phenotype. Clin Genet.
12. Carleton M, Mao M, Biery M, Warrener P, Kim S, et al. (2006) RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol 26: 3853-3863. (Pubitemid 43726402)
13. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, et al. (2006) KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 172: 363-372. (Pubitemid 43187933)
14. Ahmed SM, Theriault BL, Uppalapati M, Chiu CW, Gallie BL, et al. (2012) KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol 199: 951-967.
15. Jun DY, Park HS, Lee JY, Kim YH (2008) Regulation of the human mitotic centromere-associated kinesin (MCAK) promoter by the transcription factors Sp1 and E2F1. Biochim Biophys Acta 1779: 356-361. (Pubitemid 351645144)
16. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 1: 2643-2649.
17. Sriraksa R, Chaopatchayakul P, Jearanaikoon P, Leelayuwat C, Limpaiboon T (2010) Verification of complete bisulfite modification using Calponin-specific primer sets. Clin Biochem 43: 528-530.
18. Suva ML, Riggi N, Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339: 1567-1570.
19. Bijron JG, Bol GM, Verheijen RH, van Diest PJ (2012) Epigenetic biomarkers in the diagnosis of ovarian cancer. Expert Opin Med Diagn 6: 421-438.
20. Chiang YC, Chang MC, Chen PJ, Wu MM, Hsieh CY, et al. (2013) Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. Endocr Relat Cancer 20: 213-227.
21. Heichman KA, Warren JD (2012) DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 50: 1707-1721.
22. Ho CM, Huang CJ, Huang CY, Wu YY, Chang SF, et al. (2012) Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. Mol Cancer 11: 53.
23. Joung JG, Kim D, Kim KH, Kim JH (2013) Extracting coordinated patterns of DNA methylation and gene expression in ovarian cancer. J Am Med Inform Assoc.
24. Stefansson OA, Villanueva A, Vidal A, Marti L, Esteller M (2012) BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7: 1225-1229.
25. Wang YQ, Yan Q, Zhang JR, Li SD, Yang YX, et al. (2013) Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. J Obstet Gynaecol Res 39: 549-554.
26. Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25: 1010-1022.
27. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S (2012) The therapeutic potential of microRNAs in cancer. Cancer J 18: 275-284.
28. Zaman MS, Maher DM, Khan S, Jaggi M, Chauhan SC (2012) Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res 5: 44.
29. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, et al. (2008) Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 17: 1363-1372. (Pubitemid 351627333)
30. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, et al. (2008) Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 123: 2808-2815.
31. Madhavan J, Mitra M, Mallikarjuna K, Pranav O, Srinivasan R, et al. (2009) KIF14 and E2F3 mRNA expression in human retinoblastoma and its phenotype association. Mol Vis 15: 235-240.
32. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G (2009) Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer 124: 2071-2076.
33. Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, et al. (2013) The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics 102: 96-101.
34. Chuang JY, Wu CH, Lai MD, Chang WC, Hung JJ (2009) Overexpression of Sp1 leads to p53-dependent apoptosis in cancer cells. Int J Cancer 125: 2066-2076.
35. Davie JR, He S, Li L, Sekhavat A, Espino P, et al. (2008) Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 48: 189-208.
36. Kong LM, Liao CG, Fei F, Guo X, Xing JL, et al. (2010) Transcription factor Sp1 regulates expression of cancer-associated molecule CD147 in human lung cancer. Cancer Sci 101: 1463-1470.
37. Li L, Davie JR (2010) The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275-283.
38. Malek A, Nunez LE, Magistri M, Brambilla L, Jovic S, et al. (2012) Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7: e35130.
39. Previdi S, Malek A, Albertini V, Riva C, Capella C, et al. (2010) Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 118: 182-188.
40. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29.
41. Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, et al. (2010) The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 30: 5071-5085.
42. Zhang Q, Stovall DB, Inoue K, Sui G (2011) The oncogenic role of Yin Yang 1. Crit Rev Oncog 16: 163-197.
43. Zhou Q, Gedrich RW, Engel DA (1995) Transcriptional repression of the c-fos gene by YY1 is mediated by a direct interaction with ATF/CREB. J Virol 69: 4323-4330.
44. Usheva A, Shenk T (1996) YY1 transcriptional initiator: protein interactions and association with a DNA site containing unpaired strands. Proc Natl Acad Sci U S A 93: 13571-13576. (Pubitemid 26424160)
45. Seto E, Lewis B, Shenk T (1993) Interaction between transcription factors Sp1 and YY1. Nature 365: 462-464. (Pubitemid 23311045)
46. Austen M, Luscher B, Luscher-Firzlaff JM (1997) Characterization of the transcriptional regulator YY1. The bipartite transactivation domain is independent of interaction with the TATA box-binding protein, transcription factor IIB, TAFII55, or cAMP-responsive element-binding protein (CPB)-binding protein. J Biol Chem 272: 1709-1717. (Pubitemid 27043257)
47. Renna M, Caporaso MG, Bonatti S, Kaufman RJ, Remondelli P (2007) Regulation of ERGIC-53 gene transcription in response to endoplasmic reticulum stress. J Biol Chem 282: 22499-22512. (Pubitemid 47267309)
48. Ciocca DR, Arrigo AP, Calderwood SK (2013) Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol 87: 19-48.
49. Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 586: 1279-1286.
50. Iwaya T, Yokobori T, Nishida N, Kogo R, Sudo T, et al. (2012) Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 33: 2391-2397.
51. Sarver AL, Thayanithy V, Scott MC, Cleton-Jansen AM, Hogendoorn PC, et al. (2013) MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J Rare Dis 8: 7.
52. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, et al. (2007) Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer 46: 1-9. (Pubitemid 44772867)
53. Campbell MJ, Turner BM (2013) Altered histone modifications in cancer. Adv Exp Med Biol 754: 81-107.
54. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, et al. (2012) Systemic mirnas as potential biomarkers for malignancy. Int J Cancer 131: 2215-2222.